Document Detail

Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model.
MedLine Citation:
PMID:  11735104     Owner:  NLM     Status:  MEDLINE    
The action of recombinant factor VIIa (rFVIIa) in coagulation deficiencies with increased risk of bleeding was investigated using in vitro perfusion. Blood samples were drawn from healthy donors, a patient with hemophilia A and inhibitors, and six patients undergoing oral anticoagulant treatment. Fragmin 10 U/mL was used as anticoagulant. rFVIIa (10 microg/mL in plasma) was added to blood samples, incubated for 1 minute at 37 degrees C, and perfusion studies performed for 10 minutes at 600 x s(-1) through annular chambers containing damaged vascular segments. Subendothelial fibrin and platelets were expressed as a percentage of subendothelial surface screened. Under different conditions, rFVIIa consistently restored or improved fibrin formation on the damaged vascular subendothelium exposed to circulating blood. It restored fibrin deposition in blood from the hemophilia A patient; in patients undergoing acenocoumarol treatment, it reduced the international normalized ratio (INR) from 2.47 to 1.25 with a significant increase in fibrin deposition. Platelet deposition varied slightly between clinical conditions but was less evident in the hemophilia A patient. These data support the concept that rFVIIa facilitates fibrin formation in these clinical situations, promoting procoagulant activity at sites of vascular damage where tissue factor is exposed. This could improve hemostasis in patients with hemophilia A and inhibitors, and in patients treated with oral anticoagulants.
A M Galán; R Tonda; C Altisent; S Maragall; A Ordinas; G Escolar
Related Documents :
1521824 - Factor viii concentrates in hiv-1-positive hemophiliacs--is pure better?
8698274 - Thrombin-antithrombin iii complexes as an additional diagnostic aid in pulmonary embolism.
2245394 - Von willebrand factor in head and neck cancer.
3033024 - Gene deletions correlate with the development of alloantibodies in von willebrand disease.
2729134 - Doppler echocardiography in the assessment of the homograft aortic valve.
2587204 - Igg subclass deficiency in acute myeloid leukemia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Seminars in hematology     Volume:  38     ISSN:  0037-1963     ISO Abbreviation:  Semin. Hematol.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-12-05     Completed Date:  2002-02-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0404514     Medline TA:  Semin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  10-4     Citation Subset:  IM    
Copyright Information:
Copyright 2001 by W.B. Saunders Company.
Servicio de Hemoterapia-Hemostasia, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / pharmacology
Blood Coagulation / drug effects
Blood Platelets / cytology,  drug effects
Coagulants / pharmacology,  therapeutic use
Dalteparin / pharmacology
Factor VII / pharmacology*,  therapeutic use
Factor VIIa
Fibrin / metabolism
Hemophilia A / blood
International Normalized Ratio
Platelet Aggregation / drug effects
Recombinant Proteins / pharmacology*,  therapeutic use
Stress, Mechanical
Thrombocytopenia / drug therapy*
Reg. No./Substance:
0/Anticoagulants; 0/Coagulants; 0/Dalteparin; 0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; 9001-31-4/Fibrin; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Next Document:  Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro.